📰 Data Presented News
Page 4 - Data Presented News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Data Presented. Real-time updates on events, politics, business and more.
July 21, 2021
Diskussion Der Oberste Gerichtshof (OGH) hat im Rechtsstreit von Max Schrems mit Facebook den Europäischen Gerichtshof (EuGH) angerufen, um in einzelnen Punkten Klarheit zu schaffen. Die Fragen werfen Zweifel an der Rechtmäßigkeit der Datennutzung durch Facebook bei allen EU-Nutzern auf. So soll geklärt werden, ob die Nutzer tatsächlich - wie vom Social-Media-Konzern argumentiert - einen „Vertrag“ abschließen, weswegen die Datenschutz-Grundverordnung (DSGVO) nur eingeschränkt zutre...
May 15, 2021
Share: Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT ® ...
May 13, 2021
uniQure Inc.: uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~ LEXINGTON, Mass. and AMSTERDAM, May 13, 2021showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and...
May 13, 2021
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~ LEXINGTON, Mass. and AMSTERDAM, May 13, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etrana...
May 7, 2021
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial ...
December 14, 2020
-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- --Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021-- MIAMI, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing...